$66.95
+0.60%Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Chairman, Chief Executive Officer, President & Secretary
Compensation
$455,080
Head of Corporate Sales
Principal Financial Officer, Accounting Manager & Controller
Compensation
$157,906
Vice President of Marketing
During the last 12 months, insiders have sold $650K worth of UTMD shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
10.0K
640.90K
-641K
-$641K
0
0.00
150
9.17K
-9K
-$9K
No buying activity
Leigh Carrie
Director
$641K
Richins Paul O
Director
$6K
Koopman Brian
Officer: Principal Financial Officer
$3K
Strong bearish signal with $650K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
UTMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 04, 2025 | April 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | April 09, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2023 | April 03, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | April 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 12, 2021 | April 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 14, 2020 | July 14, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 05, 2019 | April 04, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 08, 2018 | March 06, 2018 | 2018 | |
DEF 14A DEF 14A 2016 N/A | March 10, 2017 | March 08, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.